Verona Pharma (VRP)

 

VRP Share PerformanceMore

52 week high165.00 25/05/17
52 week low100.00 15/02/18
52 week change -6.00 (-4.80%)
4 week volume427,340 27/01/18
price119.00
price date1519296665
close115.50

Media for (VRP)

Presenter: Jan-Anders Karlsson
27/07/2014

Latest NewsMore

Verona Pharma expects to report treatment trial data ahead of schedule

Verona Pharma said it expected to collect data from clinical trials of a treatment for chronic obstructive pulmonary disea...

Verona Pharma Provides Clinical Development Update

Verona Pharma Provides Clinical Development Update Accelerates top-line data readouts from ongoing clinical trials with RPL554 in COPD and CF LONDON, Feb. 13, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (Verona Pharma), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative ...

Verona Pharma plc : Block listing Interim Review

Verona Pharma plc: Block listing Interim Review LONDON, Nov. 30, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, provides the following update on its block listing, pursuant to ...

Director Deals - Verona Pharma PLC (VRP)

Dr David Ebsworth, Chairman, bought 10,000 shares in the company on the 29th November 2017 at a price of 106.85p. The...

Verona Pharma plc : PDMR Dealing

Verona Pharma plc: PDMR Dealing LONDON, Nov. 30, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that, on November 29, 2017, Dr. David Ebsworth, Non-Executive...

Broker Forecast - N+1 Singer issues a broker note on Verona Pharma PLC

N+1 Singer today reaffirms its buy investment rating on Verona Pharma PLC (LON:VRP) and set its price target at 327p.

Verona Pharma losses deepen

Verona Pharma said its third-quarter losses more than tripled after research and development costs rose. The company boo...

Verona Pharma plc Operational Update and Financial Results for the Third Quarter Ended September 30, 2017

Verona Pharma plc Operational Update and Financial Results for the Third Quarter Ended September 30, 2017 Emerging clinical data confirms the potential for RPL554 to be an important, novel treatment for patients with COPD LONDON, Nov. 07, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) ("Verona Pharma" or the "Compan...

Fundamental DataMore

EPS-0.74
Dividend yield0 %

Latest discussion posts More

  • Re: Time to load up?

    Since 2013 I believe.
    21-Feb-2018
    millwallfan
  • Re: Time to load up?

    Patience is definitely a virtue with this stock - how long have you been invested?
    21-Feb-2018
    Simonhare999
  • Re: Time to load up?

    Not such an easy decision if u average #2.30 - could be throwing good money after bad OR as a minimum 'lending' lots more for an extended period before any return. Personally ...
    13-Feb-2018
    millwallfan

Users' HoldingsMore

Users who hold Verona Pharma also hold..

Codes & Symbols

ISINGB00BYW2KH80
SymbolsVRP, LSE:VRP, VRP.L, VRP:LN, LON:VRP, XLON:VRP

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account